Search Results

BMS has so far been on a winning streak in the contingent value right cases, which allege that the pharma intentionally delayed regulatory activities for Breyanzi in order to avoid a $6.4 billion payout to Celgene shareholders.

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol Myers Squibb because it is not a properly appointed trustee for shareholders’ contingent value rights.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022.

Celgene Corporation announced that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company, Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors.

Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the world.

The U.S. Food and Drug Administration approved Celgene’s Revlimid (lenalidomide) in combination with a rituximab product for adults with previously treated follicular lymphoma or marginal zone lymphoma. It is the first FDA-approved combination therapy for patients with these forms of non-Hodgkin’s lymphoma that doesn’t include chemotherapy.

Is there still hope for Celgene shareholders who hold the $9 per share Contingent Value Rights tickets despite the cold water that seemed to dash the chances of required goals necessary for those payoffs?

In the first two weeks of September there were three scheduled PDUFA dates. One of those dates, for Celgene’s myelofibrosis drug, was approved early. Here’s a look.

Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed another TriNKET™ immunotherapy drug candidate to Celgene Corporation and its affiliates (“Celgene”).